News Daily News Weight Loss Drugs Show Promise for Secondary Prevention in PAD L.A. McKeown February 04, 2026
News Daily News Previewing 30-Year ASCVD Risk May Open Door to Earlier Treatment Yael L. Maxwell January 21, 2026
News Daily News CAC Predicts Obstructive CAD, but Thresholds Diverge by Sex L.A. McKeown January 06, 2026
News Daily News SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide Michael O'Riordan December 18, 2025
News Daily News Asundexian Reduces Recurrent Stroke Without Bleeding Risk: OCEANIC-STROKE Michael O'Riordan November 24, 2025
News Daily News Dig Deeper When Dealing With Nonobstructive CAD, AHA Urges Caitlin E. Cox November 21, 2025
News Conference News AHA 2025 POLY-HF: Polypill Pays Dividends in Patients With HFrEF Todd Neale November 14, 2025
News Conference News AHA 2025 Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV Michael O'Riordan November 08, 2025
Presentation TCT 2025 TCT 494: Cost-Effectiveness of SGLT2 Inhibitors, Statins, and GLP-1 Receptor Agonists for Cardiovascular Secondary Prevention: A Comparative Analysis Presenter: Mehmet Cilingiroglu October 28, 2025
News Conference News TCT 2025 ENCIRCLE: Good Results With Sapien M3 Transseptal TMVR Todd Neale October 27, 2025
Presentation TCT 2025 TCT 1008: Aspirin vs. Clopidogrel as Monotherapy for Secondary Prevention in Stable Coronary Artery Disease: An Updated Meta Analysis Presenter: Timothy Charles Shuey October 27, 2025
News Daily News Two New Scores Help Hone 10-Year CV Death Risk in ASCVD Patients Caitlin E. Cox October 16, 2025
News Daily News Getting Ready for a Heart Failure Polypill, Well Before the Data Are In Todd Neale October 16, 2025
News Daily News ACC: It’s Time for Clinicians to Address Inflammation in CVD Caitlin E. Cox October 03, 2025
News Conference News ESC 2025 WHF Stresses the Importance of Polypills in Global Fight Against CVD Yael L. Maxwell September 09, 2025
News Conference News ESC 2025 NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure Michael O'Riordan September 04, 2025